Valeria Tosello

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2184093/publications.pdf

Version: 2024-02-01

48 papers	3,438 citations	236925 25 h-index	254184 43 g-index
48 all docs	48 docs citations	48 times ranked	6131 citing authors

#	Article	IF	Citations
1	Î³-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nature Medicine, 2009, 15, 50-58.	30.7	417
2	Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nature Medicine, 2013, 19, 368-371.	30.7	304
3	Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8947-8952.	7.1	275
4	DNA Hydroxymethylation Profiling Reveals that WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia. Cell Reports, 2014, 9, 1841-1855.	6.4	237
5	Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia. Cancer Cell, 2013, 24, 766-776.	16.8	220
6	ETV6 mutations in early immature human T cell leukemias. Journal of Experimental Medicine, 2011, 208, 2571-2579.	8.5	184
7	Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. Nature Medicine, 2015, 21, 1182-1189.	30.7	180
8	The TLX1 oncogene drives aneuploidy in T cell transformation. Nature Medicine, 2010, 16, 1321-1327.	30.7	139
9	Alteration in Calcium Handling at the Subcellular Level inmdx Myotubes. Journal of Biological Chemistry, 2001, 276, 4647-4651.	3.4	136
10	The Side Population of Ovarian Cancer Cells Is a Primary Target of IFN-Î± Antitumor Effects. Cancer Research, 2008, 68, 5658-5668.	0.9	121
11	NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. Blood, 2008, 112, 733-740.	1.4	116
12	Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 4216-4221.	7.1	113
13	WT1 mutations in T-ALL. Blood, 2009, 114, 1038-1045.	1.4	111
14	Absence of Biallelic TCRÎ³ Deletion Predicts Early Treatment Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2010, 28, 3816-3823.	1.6	93
15	Recombinant aequorin and green fluorescent protein as valuable tools in the study of cell signalling. Biochemical Journal, 2001, 355, 1.	3.7	92
16	Targeting Nonclassical Oncogenes for Therapy in T-ALL. Cancer Cell, 2012, 21, 459-472.	16.8	84
17	The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy. Therapeutic Advances in Hematology, 2013, 4, 199-210.	2.5	76
18	Differential expression of CCR7 defines two distinct subsets of human memory CD4+CD25+ Tregs. Clinical Immunology, 2008, 126, 291-302.	3.2	46

#	Article	IF	Citations
19	Large and Dissimilar Repertoire of Melan-A/MART-1-Specific CTL in Metastatic Lesions and Blood of a Melanoma Patient. Journal of Immunology, 2002, 169, 4017-4024.	0.8	42
20	Differential Regulation of Hypoxia-Induced CXCR4 Triggering during B-Cell Development and Lymphomagenesis. Cancer Research, 2007, 67, 8605-8614.	0.9	41
21	Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors. Cancer Research, 2002, 62, 6099-107.	0.9	41
22	Chemokine receptor expression in EBV-associated lymphoproliferation in hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation. Blood, 2005, 105, 931-939.	1.4	38
23	Interferon-Î± Gene Therapy by Lentiviral Vectors Contrasts Ovarian Cancer Growth Through Angiogenesis Inhibition. Human Gene Therapy, 2005, 16, 957-970.	2.7	34
24	Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. Nature Cancer, 2020, 1, 1113-1127.	13.2	32
25	Recombinant aequorin as tool for monitoring calcium concentration in subcellular compartments. Methods in Enzymology, 2000, 327, 440-456.	1.0	28
26	Effects of CD2 locus control region sequences on gene expression by retroviral and lentiviral vectors. Blood, 2001, 98, 3607-3617.	1.4	28
27	Recruitment of human umbilical vein endothelial cells and human primary fibroblasts into experimental tumors growing in SCID mice. Experimental Cell Research, 2003, 287, 28-38.	2.6	24
28	Differential expression of constitutive and inducible proteasome subunits in human monocyteâ€derived DC differentiated in the presence of IFNâ€Î± or ILâ€4. European Journal of Immunology, 2009, 39, 56-66.	2.9	24
29	CD8+Î±Î²+T Cells That Lack Surface CD5 Antigen Expression Are a Major Lymphotactin (XCL1) Source in Peripheral Blood Lymphocytes. Journal of Immunology, 2003, 171, 4528-4538.	0.8	21
30	WT1 loss attenuates the TP53-induced DNA damage response in T-cell acute lymphoblastic leukemia. Haematologica, 2018, 103, 266-277.	3.5	21
31	miR-22-3p Negatively Affects Tumor Progression in T-Cell Acute Lymphoblastic Leukemia. Cells, 2020, 9, 1726.	4.1	17
32	Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen. Clinical Immunology, 2007, 122, 163-172.	3.2	16
33	Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with calcineurin inhibition to promote T-ALL cell death. Oncotarget, 2016, 7, 45715-45729.	1.8	16
34	Cross-talk between GLI transcription factors and FOXC1 promotes T-cell acute lymphoblastic leukemia dissemination. Leukemia, 2021, 35, 984-1000.	7.2	12
35	Expression from cell type-specific enhancer-modified retroviral vectors after transduction: influence of marker gene stability. Gene, 2002, 283, 199-208.	2.2	11
36	Heterogeneous intracellular expression of B-cell receptor components in B-cell chronic lymphocytic leukaemia (B-CLL) cells and effects of CD79b gene transfer on surface immunoglobulin levels in a B-CLL-derived cell line. British Journal of Haematology, 2005, 130, 878-889.	2.5	11

#	Article	IF	Citations
37	Insights on Metabolic Reprogramming and Its Therapeutic Potential in Acute Leukemia. International Journal of Molecular Sciences, 2021, 22, 8738.	4.1	11
38	The HOX11/TLX1 Transcription Factor Oncogene Induces Chromosomal Aneuploidy in T-ALL.. Blood, 2009, 114, 142-142.	1.4	8
39	A Novel Class of Activating Mutations in NOTCH1 in T-ALL.. Blood, 2007, 110, 694-694.	1.4	5
40	An Oncogenic Metabolic Switch Mediates Resistance to NOTCH1 Inhibition in T-ALL. Blood, 2012, 120, 285-285.	1.4	5
41	Inhibition of NOTCH1 Signaling Reverses Glucocorticoid Resistance in T-ALL.. Blood, 2007, 110, 151-151.	1.4	4
42	Inhibition of NOTCH1 Signaling and Glucocorticoid Therapy in T-ALL. Blood, 2008, 112, 298-298.	1.4	3
43	Therapeutic Utility of PI3KÎ³ Inhibition in Leukemogenesis and Tumor Cell Survival. Blood, 2012, 120, 1492-1492.	1.4	1
44	Interferon- Gene Therapy by Lentiviral Vectors Contrasts Ovarian Cancer Growth Through Angiogenesis Inhibition. Human Gene Therapy, 2005, .	2.7	0
45	Oncogenic Transcriptional Programs Controlled by TLX1/HOX11 and TLX3/HOX11L2 in T-ALL.. Blood, 2009, 114, 676-676.	1.4	0
46	BCL11B Mutations In T-Cell Acute Lymphoblastic Leukemia. Blood, 2010, 116, 471-471.	1.4	0
47	Identification of NOTCH1-Controlled Transcriptional Programs In Human T-Cell Development. Blood, 2010, 116, 2495-2495.	1.4	0
48	DNA Hydroxymethylation Profiling Reveals That WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia. Blood, 2014, 124, 365-365.	1.4	0